PH12021500006A1 - Methods of treatment and prevention of alzheimer's disease - Google Patents
Methods of treatment and prevention of alzheimer's diseaseInfo
- Publication number
- PH12021500006A1 PH12021500006A1 PH12021500006A PH12021500006A PH12021500006A1 PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1 PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A PH12021500006 A PH 12021500006A PH 12021500006 A1 PH12021500006 A1 PH 12021500006A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- disease
- alzheimer
- subject
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021500006A1 true PH12021500006A1 (en) | 2021-09-13 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021500006A PH12021500006A1 (en) | 2018-07-24 | 2021-01-21 | Methods of treatment and prevention of alzheimer's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (https=) |
| EP (1) | EP3826674A2 (https=) |
| JP (2) | JP7541505B2 (https=) |
| KR (1) | KR20210039402A (https=) |
| CN (2) | CN118924896A (https=) |
| AU (1) | AU2019309938B2 (https=) |
| BR (1) | BR112021001272A2 (https=) |
| CA (1) | CA3107370A1 (https=) |
| IL (3) | IL310132B2 (https=) |
| MX (1) | MX2021000778A (https=) |
| PH (1) | PH12021500006A1 (https=) |
| TW (1) | TW202019471A (https=) |
| WO (1) | WO2020023530A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| KR20220156534A (ko) * | 2020-03-20 | 2022-11-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고농도 항-Aβ 프로토피브릴 항체 제형물 및 이의 사용 방법 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| WO2022035758A1 (en) * | 2020-08-12 | 2022-02-17 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| KR20240115910A (ko) * | 2021-12-17 | 2024-07-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법 |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| MX2024009492A (es) * | 2022-02-02 | 2024-08-09 | Eisai R&D Man Co Ltd | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| RU2476431C2 (ru) | 2008-01-18 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конденсированное производное аминодигидротиазина |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| JP2013521233A (ja) * | 2010-02-25 | 2013-06-10 | ヤンセン アルツハイマー イミュノセラピー | Ａβを標的とする免疫療法のＰＥＴモニタリング |
| CA2789963C (en) | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| US8426584B2 (en) | 2011-01-21 | 2013-04-23 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
| EP3166970B1 (en) * | 2014-07-10 | 2021-03-10 | BioArctic AB | Improved a-beta protofibril binding antibodies |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| BR112018014762A2 (pt) * | 2016-01-20 | 2018-12-26 | Genentech Inc | método de tratamento da doença de alzheimer (da) precoce |
| ES2939373T3 (es) * | 2016-05-13 | 2023-04-21 | Pasteur Institut | Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN117244056A (zh) * | 2016-10-27 | 2023-12-19 | 卫材研究发展管理有限公司 | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 |
-
2019
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt active IP Right Grant
- 2019-07-23 IL IL310132A patent/IL310132B2/en unknown
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 AU AU2019309938A patent/AU2019309938B2/en active Active
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019309938A1 (en) | 2021-03-11 |
| IL280315B2 (en) | 2024-06-01 |
| WO2020023530A3 (en) | 2020-03-12 |
| EP3826674A2 (en) | 2021-06-02 |
| IL280315A (en) | 2021-03-25 |
| WO2020023530A2 (en) | 2020-01-30 |
| AU2019309938B2 (en) | 2026-04-02 |
| CN118924896A (zh) | 2024-11-12 |
| CA3107370A1 (en) | 2020-01-30 |
| JP7541505B2 (ja) | 2024-08-28 |
| KR20210039402A (ko) | 2021-04-09 |
| BR112021001272A2 (pt) | 2021-04-27 |
| CN112805031A (zh) | 2021-05-14 |
| TW202019471A (zh) | 2020-06-01 |
| IL280315B1 (en) | 2024-02-01 |
| IL310132B1 (en) | 2025-11-01 |
| IL310132B2 (en) | 2026-03-01 |
| IL323583A (en) | 2025-11-01 |
| US20210324056A1 (en) | 2021-10-21 |
| IL310132A (en) | 2024-03-01 |
| JP2024112859A (ja) | 2024-08-21 |
| MX2021000778A (es) | 2021-03-31 |
| JP2021532126A (ja) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021500006A1 (en) | Methods of treatment and prevention of alzheimer's disease | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| FI3927337T3 (fi) | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikea-asteisen masennuksen hoitoon | |
| MX2012002082A (es) | Terapia de acetato de glatiramero de baja frecuencia. | |
| MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| EP3708168A3 (en) | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia | |
| MX361741B (es) | Tratamientos médicos a base de anamorelina. | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2024010655A (es) | Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| MX2024002567A (es) | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. | |
| MX2022003010A (es) | Tratamiento de la emr mediante cambio de terapia. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| MX2021013807A (es) | Tratamiento de enfermedad ocular. | |
| IL285160A (en) | Low dose pridopidine for parkinson’s disease and other diseases associated with parkinsonism | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
| EP4523750A3 (en) | Methods of reducing cerebrovascular events in patients with fabry disease | |
| MX2024005084A (es) | Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada. | |
| MX2021008986A (es) | Metodos de tratamiento de un paciente con enfermedad de parkinson. |